| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 1 | -700 | 100% | $306.18 | -$214,289 |
| Net | -1 | -700 | -100% | -$214,289 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James Barry | BIO | Bio-Rad A Common Stock | Sale | -57.9% | $214,289 | $306.18 | -700 | 510 | 06 Nov 2025 | Direct |
| Jonathan P. DiVincenzo | BIO | Bio-Rad A Common Stock | Tax liability | -50.8% | -950 | 919 | 24 Oct 2025 | Direct | ||
| Jonathan P. DiVincenzo | BIO | Bio-Rad A Common Stock | Options Exercise | 1,869 | 1,869 | 24 Oct 2025 | Direct | |||
| Jonathan P. DiVincenzo | BIO | Restricted Stock Units | Options Exercise | -25% | -1,869 | 5,609 | 24 Oct 2025 | Direct | ||
| Sedat Evran | BIO | Bio-Rad A Common Stock | Tax liability | -13% | -335 | 2,233 | 20 Oct 2025 | Direct | ||
| Sedat Evran | BIO | Bio-Rad A Common Stock | Options Exercise | 68.5% | 1,044 | 2,568 | 20 Oct 2025 | Direct | ||
| Sedat Evran | BIO | Restricted Stock Units | Options Exercise | -33.3% | -1,044 | 2,088 | 20 Oct 2025 | Direct | ||
| Sedat Evran | BIO | Bio-Rad A Common Stock | Tax liability | -15.4% | -277 | 1,524 | 06 Sep 2025 | Direct | ||
| Sedat Evran | BIO | Bio-Rad A Common Stock | Options Exercise | 92.2% | 864 | 1,801 | 06 Sep 2025 | Direct | ||
| Sedat Evran | BIO | Restricted Stock Units | Options Exercise | -25% | -864 | 2,592 | 06 Sep 2025 | Direct | ||
| Roop K. Lakkaraju | BIO | Bio-Rad A Common Stock | Tax liability | -23% | -550 | 1,844 | 06 Sep 2025 | Direct | ||
| Roop K. Lakkaraju | BIO | Bio-Rad A Common Stock | Options Exercise | 178.8% | 1,535 | 2,394 | 06 Sep 2025 | Direct | ||
| Roop K. Lakkaraju | BIO | Restricted Stock Units | Options Exercise | -25% | -1,535 | 4,608 | 06 Sep 2025 | Direct | ||
| Colleen Corey | BIO | Bio-Rad A Common Stock | Tax liability | -1.06% | -209 | 19,550 | 06 Sep 2025 | Direct | ||
| Colleen Corey | BIO | Bio-Rad A Common Stock | Options Exercise | 3% | 576 | 19,759 | 06 Sep 2025 | Direct | ||
| Colleen Corey | BIO | Restricted Stock Units | Options Exercise | -25% | -576 | 1,728 | 06 Sep 2025 | Direct | ||
| James Barry | BIO | Bio-Rad A Common Stock | Tax liability | -23.8% | -378 | 1,210 | 06 Sep 2025 | Direct | ||
| James Barry | BIO | Bio-Rad A Common Stock | Options Exercise | 198.7% | 1,056 | 1,588 | 06 Sep 2025 | Direct | ||
| James Barry | BIO | Restricted Stock Units | Options Exercise | -25% | -1,056 | 3,168 | 06 Sep 2025 | Direct | ||
| Allison Schwartz | BIO | Bio-Rad A Common Stock | Tax liability | -2.22% | -33 | 1,456 | 06 Sep 2025 | Direct | ||
| Allison Schwartz | BIO | Bio-Rad A Common Stock | Options Exercise | 6.59% | 92 | 1,489 | 06 Sep 2025 | Direct | ||
| Allison Schwartz | BIO | Restricted Stock Units | Options Exercise | -24.9% | -92 | 277 | 06 Sep 2025 | Direct | ||
| Eva Anette Engelhardt | BIO | Bio-Rad A Common Stock | Tax liability | -31.6% | -413 | 896 | 06 Sep 2025 | Direct | ||
| Eva Anette Engelhardt | BIO | Bio-Rad A Common Stock | Options Exercise | 733.8% | 1,152 | 1,309 | 06 Sep 2025 | Direct | ||
| Eva Anette Engelhardt | BIO | Restricted Stock Units | Options Exercise | -25% | -1,152 | 3,456 | 06 Sep 2025 | Direct | ||
| Courtney C. Enloe | BIO | Bio-Rad A Common Stock | Tax liability | -30.4% | -275 | 629 | 06 Sep 2025 | Direct | ||
| Courtney C. Enloe | BIO | Bio-Rad A Common Stock | Options Exercise | 564.8% | 768 | 904 | 06 Sep 2025 | Direct | ||
| Courtney C. Enloe | BIO | Restricted Stock Units | Options Exercise | -25% | -768 | 2,304 | 06 Sep 2025 | Direct | ||
| Norman D. Schwartz | BIO | Bio-Rad A Common Stock | Tax liability | -0.34% | -1,528 | 443,434 | 06 Sep 2025 | Direct | ||
| Norman D. Schwartz | BIO | Bio-Rad A Common Stock | Options Exercise | 0.78% | 3,455 | 444,962 | 06 Sep 2025 | Direct | ||
| Norman D. Schwartz | BIO | Restricted Stock Units | Options Exercise | -25% | -3,455 | 10,367 | 06 Sep 2025 | Direct | ||
| Sedat Evran | BIO | Restricted Stock Units | Award | 4,110 | 4,110 | 05 Sep 2025 | Direct | |||
| Roop K. Lakkaraju | BIO | Restricted Stock Units | Award | 5,480 | 5,480 | 05 Sep 2025 | Direct | |||
| Colleen Corey | BIO | Restricted Stock Units | Award | 2,740 | 2,740 | 05 Sep 2025 | Direct | |||
| James Barry | BIO | Restricted Stock Units | Award | 4,110 | 4,110 | 05 Sep 2025 | Direct | |||
| Allison Schwartz | BIO | Restricted Stock Units | Award | 914 | 914 | 05 Sep 2025 | Direct | |||
| Jonathan P. DiVincenzo | BIO | Restricted Stock Units | Award | 6,850 | 6,850 | 05 Sep 2025 | Direct | |||
| Eva Anette Engelhardt | BIO | Restricted Stock Units | Award | 4,110 | 4,110 | 05 Sep 2025 | Direct | |||
| Courtney C. Enloe | BIO | Restricted Stock Units | Award | 2,740 | 2,740 | 05 Sep 2025 | Direct | |||
| Norman D. Schwartz | BIO | Restricted Stock Units | Award | 16,439 | 16,439 | 05 Sep 2025 | Direct | |||
| Rajat Mehta | BIO | Restricted Stock Units | Award | 7,307 | 5,480 | 05 Sep 2025 | Direct | |||
| Allison Schwartz | BIO | Bio-Rad A Common Stock | Tax liability | -3.79% | -55 | 1,397 | 01 Sep 2025 | Direct | ||
| Allison Schwartz | BIO | Bio-Rad A Common Stock | Options Exercise | 11.3% | 147 | 1,452 | 01 Sep 2025 | Direct | ||
| Allison Schwartz | BIO | Restricted Stock Units | Options Exercise | -100% | -147 | 0 | 01 Sep 2025 | Direct | ||
| James Barry | BIO | Bio-Rad A Common Stock | Tax liability | -29% | -217 | 532 | 01 Sep 2025 | Direct | ||
| James Barry | BIO | Bio-Rad A Common Stock | Options Exercise | 410.8% | 602 | 749 | 01 Sep 2025 | Direct | ||
| James Barry | BIO | Restricted Stock Units | Options Exercise | -100% | -602 | 0 | 01 Sep 2025 | Direct | ||
| Colleen Corey | BIO | Bio-Rad A Common Stock | Tax liability | -2.03% | -398 | 19,183 | 01 Sep 2025 | Direct | ||
| Colleen Corey | BIO | Bio-Rad A Common Stock | Options Exercise | 5.96% | 1,102 | 19,581 | 01 Sep 2025 | Direct | ||
| Colleen Corey | BIO | Restricted Stock Units | Options Exercise | -100% | -1,102 | 0 | 01 Sep 2025 | Direct |